Product image of Intelence (Etravirine) supplied by GNH India

Intelence

Active Ingredient:
Etravirine
Origin:
EU

Intelence (Etravirine)

Etravirine, the active ingredient in Intelence, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the management of HIV‑1 infection, typically as part of combination antiretroviral therapy for adults and adolescents.

GNH India supplies Intelence as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Manufacturer / TM Owner

Janssen-Cilag International Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Etravirine is indicated for HIV‑1 infection and is used as part of combination antiretroviral regimens.
  • HIV‑1 infection (treatment‑naïve patients): contributes to viral load reduction when combined with other antiretrovirals.
  • HIV‑1 infection (treatment‑experienced patients with NNRTI resistance): offers an alternative option to achieve viral suppression.
  • HIV‑1 infection (in combination with a protease inhibitor): enhances regimen potency in patients requiring intensified therapy.

How It Works

  • Etravirine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that inhibits the transcription of viral RNA. This blockade prevents the synthesis of viral DNA, thereby halting replication of the virus within infected cells.

Side Effects

Etravirine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Rash: skin erythema that may be pruritic.
  • Headache: transient cephalic pain.
  • Fatigue: generalized tiredness.

Serious or Rare Side Effects

  • Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate discontinuation.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Hypersensitivity reactions: including angioedema and anaphylaxis.

Precautions & Warnings

  • When prescribing Etravirine, clinicians should consider several precautionary measures.
  • Assess hepatic function: evaluate liver enzymes before initiation.
  • Monitor for rash: discontinue if severe skin reactions develop.
  • Check drug interactions: review concomitant medications for CYP3A4 inducers.
  • Pregnancy and breastfeeding: weigh benefits against potential risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Etravirine interacts with several agents that can alter its plasma concentrations or efficacy.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce Etravirine levels.
  • Potent CYP2C9 inhibitors (e.g., fluconazole): may increase exposure, risk of toxicity.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
  • Protease inhibitors boosted with ritonavir: can increase Etravirine concentrations; monitor for adverse effects.
  • Other NNRTIs (e.g., efavirenz): may have additive toxicity; adjust regimen accordingly.

Frequently Asked Questions

Intelence contains the active ingredient Etravirine and is used as part of combination antiretroviral therapy to treat HIV‑1 infection in adults and adolescents. It helps suppress viral replication when given with other approved HIV medicines.

Etravirine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a structural change that blocks the transcription of viral RNA into DNA. This inhibition prevents the virus from replicating inside host cells.

The prescribed dose of Intelence is determined by the treating clinician based on the patient’s clinical status, resistance profile, and the other antiretroviral agents in the regimen. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for Etravirine in pregnancy and lactation are limited. Clinicians should weigh the potential benefits of viral suppression against any possible risks to the fetus or infant, and consider alternative options when appropriate.

To request Intelence, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with earlier NNRTIs such as efavirenz, Etravirine offers a broader resistance profile and may be effective in patients with certain NNRTI‑resistant HIV strains. However, individual response varies, and selection should be guided by resistance testing and clinical judgment.

Intelence tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and avoid exposure to extreme heat.

Intelence is taken orally, usually with food to improve tolerability. The tablets are swallowed whole with a glass of water, and dosing times should be consistent each day as directed by the prescriber.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, hepatic toxicity manifested by elevated liver enzymes or hepatitis, and hypersensitivity reactions that may lead to anaphylaxis. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to Etravirine or any component of the tablet should avoid Intelence. Additionally, individuals taking strong CYP3A4 inducers that markedly reduce drug exposure may not achieve therapeutic benefit and should discuss alternatives with their clinician.

Reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry)

Content approved 11 Aug 2026

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Etravirine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT